Can We Design a Nogo Receptor-Dependent Cellular Therapy to Target MS?
Min Joung Kim(Monash University), Steven Petratos(Australian Regenerative Medicine Institute), Nikolaos Grigoriadis(Unknown), Paschalis Theotokis(AHEPA University Hospital), Jung Hee Kang(Monash University)
Cited by 228
Related Papers
Where are Europe’s last primary forests?
|Diversity and Distributions|2018|454
Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron
|Journal of Neurology Neurosurgery & Psychiatry|2014|355
Neuroprotection and Immunomodulation With Mesenchymal Stem Cells in Chronic Experimental Autoimmune Encephalomyelitis
|Archives of Neurology|2008|338
Clinical Relevance of Brain Volume Measures in Multiple Sclerosis
|CNS Drugs|2014|293
Diagnosis and classification of optic neuritis
|The Lancet Neurology|2022|290